Oncotarget

Research Papers:

Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus

Tian-Zhu Yu, Wen Zhang, Qing-Xin Liu, Wen-Hui Li, Jing-Qin Ma, Zi-Han Zhang, Min-Jie Yang, Jian-Hua Wang, Bing Chen, Shao-Chong Zeng, Jian-Jun Luo _, Ling-Xiao Liu and Zhi-Ping Yan

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:12108-12119. https://doi.org/10.18632/oncotarget.14520

Metrics: PDF 1813 views  |   HTML 2323 views  |   ?  


Abstract

Tian-Zhu Yu1,2,*, Wen Zhang1,2,*, Qing-Xin Liu1,2,*, Wen-Hui Li4,*, Jing-Qin Ma1,2, Zi-Han Zhang1,2, Min-Jie Yang1,2, Jian-Hua Wang1,2, Bing Chen3, Shao-Chong Zeng3, Jian-Jun Luo1,2, Ling-Xiao Liu1,2, Zhi-Ping Yan1,2

1Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China

2Shanghai Institute of Medical Imaging, Shanghai, China

3Department of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, China

4Department of Interventional Radiology, Yancheng Third People’s Hospital, Southeast University, Yancheng, China

*These authors have contributed equally to this work

Correspondence to:

Jian-Jun Luo, email: [email protected]

Ling-Xiao Liu, email: [email protected]

Zhi-Ping Yan, email: [email protected]

Keywords: hepatocellular carcinoma, main portal vein, tumor thrombus, endovascular brachytherapy, three-dimensional conformal radiotherapy

Received: October 20, 2016    Accepted: December 27, 2016    Published: January 05, 2017

ABSTRACT

Hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus have a median survival time of only about 4 months. We therefore compared the safety and efficacy of endovascular brachytherapy (EVBT) and sequential three-dimensional conformal radiotherapy (3-DCRT). From a cohort of 176 patients, we treated 123 with EVBT using iodine-125 seed strands (group A) and the remaining 53 with sequential 3-DCRT (group B). Overall survival, progression free survival and stent patency characteristics were compared between the two groups. Our analysis demonstrated a median survival of 11.7 ± 1.2 months in group A versus 9.5 ± 1.8 months in group B (p = 0.002). The median progression free survival was 5.3 ± 0.7 months in groupA versus 4.4 ± 0.4 months in group B (p = 0.010). The median stent patency period was 10.3 ± 1.1 months in group A versus 8.7 ± 0.7 months in group B (p = 0.003). Therefore, as compared to sequential 3-DCRT, EVBT combined with portal vein stenting and TACE improved overall survival of HCC patients with main portal vein tumor thrombus.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14520